HOME >> BIOLOGY >> NEWS
New Company Formed Through Licensing Of Cardiac-Hypertrophy Technology From Texas Institutions

DALLAS - November 18, 1998 - ManTex Biotech Inc., a company based on discoveries concerning enlargement of the heart by researchers at UT Southwestern Medical Center at Dallas and the University of North Texas Health Science Center, Fort Worth, today announced joint licensing of the technologies with the two medical institutions.

"We have made exciting progress toward understanding cardiac hypertrophy and heart failure," said Dr. Eric Olson, chairman of molecular biology and oncology at UT Southwestern and a world-renowned heart researcher. "In particular, the discovery of a calcium-signaling system that controls cardiac enlargement and the development of genetically engineered mice that mimic human heart disease, represent powerful new approaches for drug discovery. These approaches, which will be the foundation of ManTex Biotech, should lead to the rapid development of new strategies for treatment of heart disease."

Cardiac hypertrophy, which involves enlargement of the heart, is the organ's natural response to stress, including that from hypertension or heart attacks. Although initially beneficial, the enlargement eventually weakens the heart, causing it to behave like spent elastic.

"These are the first really good genetic models that target cardiac enzymes and appear to constitute the master switch in the process of cardiac hypertrophy," said Dr. Stephen Grant, director of UNT Health Science Center's cardiac and vascular molecular genetics laboratory. "We found that if this switch is left on, hearts enlarge, dramatically increasing the potential for heart failure."

The discoveries received international attention when presented in the April 17, 1998 issue of Cell. The cover article reported that two existing drugs, cyclosporine A and FK 506, could prevent hypertrophy in mice by targeting the enzyme calcineurin. At last week's American Heart Association meeting in Dallas, Olson presented additional licensed discoveries
'"/>

Contact: Susan Steeves
susan.steeves@email.swmed.edu
214-648-3404
UT Southwestern Medical Center
18-Nov-1998


Page: 1 2

Related biology news :

1. Ferr-Damar wins 2004 Eli Lilly and Company Research Award
2. Open access initiative from the Company of Biologists
3. ESA Corporate Award winner 2001: Weyerhaeuser Company Limited British Columbia Coastal Forest Project Team
4. Warner-Lambert Company gift creates bioinformatics program
5. SFU Spin-Off Company To Research Promising Antibacterial Agents
6. Move Over, Protein Kinase C, Youve Got Company: Munc13-1 Is A Novel Diacylglycerol Target That Modulates Neurotransmitter Release
7. Perkin-Elmer, Dr. J. Craig Venter, And TIGR Announce Formation Of New Genomics Company
8. New Company To Turn UNC-CH, Army Inventions Into Improved Vaccines
9. Florida Company Using ORNL Technology For Revolutionary Wheelchair
10. MelTec GmbH announces new technology for High-Throughput Topological Analysis of human cells
11. "Protect Wild Dolphins" License Plate Sales To Fund Wild Dolphin Research Efforts Throughout Florida

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/25/2019)... ... September 25, 2019 , ... LeadingBiotech , ... dialogue, today announces its inaugural South CEO conference to be held ... , Co-produced by Tulane University, this invitation-only meeting convenes biopharma executives to discuss ...
(Date:9/24/2019)... (PRWEB) , ... September 24, 2019 , ... ... its technology driven portfolio of 3D porous titanium spinal implants with the expansion ... Ti3D implant offerings while more than tripling the number of cervical and lumbar ...
(Date:9/22/2019)... ... September 20, 2019 , ... ... are adjusting to client demands for precision medicine products. The report, Lab ... $19 billion in 2018, the pharma/bio sector is the largest source of demand ...
Breaking Biology News(10 mins):
(Date:10/3/2019)... ... 02, 2019 , ... Rapid Novor, Inc., the world's leader ... has moved into a new, 5000 sqft, purpose-built, state-of-the-art facility. Now home to ... company's continuous commitment to quality research and service offerings. , The ...
(Date:9/24/2019)... ... September 24, 2019 , ... ... delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and ... company focused on the development of therapies to treat central nervous system ...
(Date:9/17/2019)... ... September 17, 2019 , ... Catalent, a ... and Clinical Supplies Management, Asia Pacific (APAC) will present at the upcoming 3rd ... Sept. 25-26, 2019. , On Thursday, Sept. 26, at 10:10 a.m., Ms. Delaney ...
(Date:9/17/2019)... , ... September 16, 2019 , ... ... via CNBC on Saturday, September 21st @11:00am ET. Check local listings for more ... Ltd. (Credo Biomedical), a molecular diagnostic company from Singapore dedicated to developing ...
Breaking Biology Technology:
Cached News: